Agendia and UZ Leuven Partner to Co-Validate MammaPrint BluePrint Breast Cancer Risk of Recurrence and Molecular Subtyping Kit Ahead of European Launch
IRVINE, CA, AMSTERDAM, NETHERLANDS โ 7 December 2017 โ Agendia, Read More
Agendia Collaborates with Prestigious Cancer Center, Institut Curie, for MammaPrint BluePrint Breast Cancer Kit Co-Validation Study
Institut Curie is one of an increasing number of major Read More
New Data at the San Antonio Breast Cancer Symposium Demonstrate the Value of MammaPrint and BluePrint Across Breast Cancer Patient Populations
IRVINE, CA, AMSTERDAM, NETHERLANDS โ 30 November 2017 โ Agendia, Read More
Agendiaโs MammaPrint Breast Cancer Risk-of-Recurrence Test Obtains Favorable Final Payment Determination from CMS for New, Unique Category 1 CPT Code
CMS established the 2018 payment rate for MammaPrintโs new CPT Read More
AJCC Confirms MammaPrintโs Clinical Utility for Treatment Decisions and Staging in Recent 8th Edition Breast Chapter Update
Update clarifies that the patient and clinician may choose any Read More
New Study Published in JAMA Oncology Shows MammaPrint Changed Breast Cancer Treatment Decisions in 3 out of 4 Cases where Guidance was Unclear with the 21-Gene Assay
Prospective PROMIS trial showed no correlation between the two tests Read More
Breast Cancer is the Most Feared Cancer Among Women in Germany, Although Less than Half are Aware of the Benefits of Genomic Testing
KANTAR survey: Only 40% of breast cancer patients know the Read More
Breast Cancer โ Letโs Make It Personal: Agendia Supports Breast Cancer Awareness Month with International Program of Activities
Flash Mob for Breast Cancer Empowerment, in partnership with the Read More
10-Year Prospective Outcome Data and MINDACT Sub-Study Presented at ESMO Congress Demonstrate Prognostic Value of MammaPrint in Personalizing Early-Stage Breast Cancer Treatment
First time 10-year prospective outcome data confirms clinical utility of Read More
Agendiaโs MammaPrint Recommended by ASCO Breast Cancer Guideline in Focused Update Based on Landmark MINDACT Trial Data
ASCOยฎ recommends MammaPrintยฎ for clinical high risk, hormone receptor-positive, HER2-negative Read More
